XNYS
PRGO
Market cap1.87bUSD
Sep 17, Last price
13.48USD
1D
-0.15%
1Q
32.10%
Jan 2017
-83.73%
Name
Perrigo Company PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Related entities
Subsidiaries (9)
GALPHARM INTERNATIONAL LIMITED
OMEGA PHARMA BELGIUM
OMEGA PHARMA INVEST NV
OMEGA PHARMA NV
PERRIGO CAPITAL
PERRIGO FINANCE UNLIMITED COMPANY
Perrigo Investments, LLC
PERRIGO UK ACQUISITION LIMITED
WRAFTON LABORATORIES LIMITED
Key people
Robert Willis
Chief Human Resource Officer, Executive Vice President · since 2019
Svend Andersen
Executive Vice President, President - Consumer Healthcare International · since 2017
Thomas M. Farrington
Executive Vice President, Chief Information Officer · since 2015
Ronald Craig Janish
Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer · since 2019
Jeffrey R. Needham
Executive Vice President, President - Consumer Healthcare Americas · since 2009
Grainne Quinn
Executive Vice President, Chief Medical Officer · since 2016
Raymond P. Silcock
Chief Financial Officer, Executive Vice President · since 2019
James E. Dillard
Executive Vice President, Chief Scientific Officer · since 2019
Todd W. Kingma
Executive Vice President, General Counsel, Company Secretary · since 2006
John T. Hendrickson
President, Director · since 2017
Murray S. Kessler
President, Chief Executive Officer, Director · since 2018
Independent Director · since 2017
Marry Laurie Brlas
Independent Chairman of the Board · since 2016
Independent Director · since 2017
Independent Director · since 2017
Independent Director · since 2014
Independent Director · since 2016
Independent Director · since 2017
Headquarters & legal address
THE SHARP BUILDING
HOGAN PLACE
DUBLIN 2
DUBLIN, D D02 TY74
IE
HOGAN PLACE
DUBLIN 2
DUBLIN, D D02 TY74
IE
Previous name
BLISFONT LIMITED
Previous name
PERRIGO COMPANY LIMITE
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||